全文获取类型
收费全文 | 2692篇 |
免费 | 105篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 112篇 |
儿科学 | 163篇 |
妇产科学 | 91篇 |
基础医学 | 172篇 |
口腔科学 | 71篇 |
临床医学 | 182篇 |
内科学 | 559篇 |
皮肤病学 | 30篇 |
神经病学 | 256篇 |
特种医学 | 114篇 |
外科学 | 725篇 |
综合类 | 34篇 |
预防医学 | 34篇 |
眼科学 | 72篇 |
药学 | 90篇 |
中国医学 | 1篇 |
肿瘤学 | 113篇 |
出版年
2024年 | 2篇 |
2023年 | 16篇 |
2022年 | 17篇 |
2021年 | 52篇 |
2020年 | 38篇 |
2019年 | 56篇 |
2018年 | 57篇 |
2017年 | 35篇 |
2016年 | 90篇 |
2015年 | 96篇 |
2014年 | 105篇 |
2013年 | 138篇 |
2012年 | 176篇 |
2011年 | 150篇 |
2010年 | 106篇 |
2009年 | 93篇 |
2008年 | 202篇 |
2007年 | 233篇 |
2006年 | 211篇 |
2005年 | 226篇 |
2004年 | 196篇 |
2003年 | 175篇 |
2002年 | 139篇 |
2001年 | 40篇 |
2000年 | 31篇 |
1999年 | 24篇 |
1998年 | 23篇 |
1997年 | 10篇 |
1996年 | 11篇 |
1995年 | 8篇 |
1994年 | 6篇 |
1993年 | 5篇 |
1992年 | 4篇 |
1991年 | 12篇 |
1990年 | 12篇 |
1989年 | 7篇 |
1988年 | 5篇 |
1984年 | 4篇 |
1983年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 2篇 |
1977年 | 1篇 |
1966年 | 2篇 |
排序方式: 共有2819条查询结果,搜索用时 31 毫秒
101.
A 28-year-old woman underwent a pylorus preserving Whipple procedure for pancreatic serous cystadenoma located on the head of the pancreas. During the operation, an internal stent (7F silastic catheter, 9 cm in length) was placed within the pancreatic duct in the area of pancreaticojejunal end-to-end Dunking type anastomosis to prevent development of fistula. The stent was positioned so that one third of its length would lie into the pancreatic duct, and it was anchored to the periductal pancreatic tissue with only one rapidly absorbable chromic suture. Leakage from the anastomosis was not observed, and she was discharged without any complaint. Early postoperative abdominal CT examination revealed that the stent was retained within the normal caliber pancreatic duct (Fig. 1a). Six months after the operation, she began to complain to epigastric pain triggered by the meals. The laboratory analysis was normal, particularly liver biochemical tests and serum amylase. The internal pancreatic stent within the dilated pancreatic duct was detected by an additional CT examination (Fig. 1b). The stent was removed endoscopically at the third attempt. The pain was resolved after its removal. Control CT examination which was taken at the 18th month after removal of the stent showed dilatation of the pancreatic duct (Fig. 2a). The patient remained free of any complaint, although regressed pancreatic duct dilatation has persisted over 4 years of follow-up (Fig. 2b). 相似文献
102.
Cetin Ozener Ibrahim Karayaylali Cengiz Utas Semra Bozfakioglu Tekin Akpolat 《Renal failure》2014,36(2):149-153
Purpose: It is well established that diabetic peritoneal dialysis (PD) patients have a higher mortality rate than the other PD population. This study was designed to determine the overall predictors of survival and compared mortality and morbidity between diabetic and non-diabetic Turkish PD patients. Methods: We conducted a multicenter retrospective study with 915 PD patients [217 had diabetes mellitus (DM)]. Serum albumin, PTH, HbA1c, co-morbid diseases, dialysis adequacy (Kt/V), and peritoneal transport characteristics as well as peritonitis episodes and ultrafiltration failure during the follow-up period were recorded. Results: DM patients were older and had more co-morbidities than non-DM patients. Peritonitis rates were higher in DM patients (one episode per 35.9 patient months) compared to non-DM patients (one episode per 41.5 patient months) (p?0.001). On Kaplan–Meier analysis, patient survival was significantly lower in DM patients with the 2-, 3- and 5-year patient survival rates of 90.8%, 87.8% and 78.2% in non-diabetics and 80.9%, 70.4% and 61.2% in diabetics, respectively. On Cox regression analysis, DM (HR 1.5, p?=?0.022), age (HR 1.03, p?0.001), baseline serum albumin (HR 0.39, p?0.001), heart failure (HR 0.038, p?=?0.038), peripheral artery disease (HR 1.83, p?=?0.025) and amputation (HR 4.1, p?=?0.009) at baseline were significant predictors of overall mortality. Conclusions: Patient survival is lower in diabetic compared to non-diabetic patients on PD. Peritonitis rates were also higher in diabetic PD patients. DM, older age, albumin level and cardiovascular co-morbidities are predictors of mortality 相似文献
103.
Cengiz Candan Nur Canpolat Selman Gökalp Nurdan Yıldız Pınar Turhan Mehmet Taşdemir Lale Sever Salim Çalışkan 《Pediatric nephrology (Berlin, Germany)》2014,29(1):95-102
Background
The aim of this study was to evaluate the presence of subclinical cardiovascular disease (CVD) and its relation to risk factors in pediatric patients with steroid-resistant nephrotic syndrome (NS).Methods
Thirty-seven patients with normal renal function were compared with 22 healthy controls regarding the presence of subclinical CVD. Measurements included aortic pulse wave velocity (PWV), carotid intima media thickness (IMT), and left ventricular mass (LVM). Patients were additionally assessed for blood pressure (BP) pattern and the presence of hypertension by 24-h ambulatory blood pressure monitoring.Results
Compared with the controls, patients had significantly higher mean aortic PWV-standard deviation scores (SDS), mean carotid IMT-SDS, and LVM index (p?<?0.001 for all). Increased aortic PWV was noted in 5 % of patients, increased carotid IMT in 22 %, and increased LVM index in 19 %. Five patients (14 %) were hypertensive, and mean BP indexes, SDS, and BP loads during nighttime were significantly higher than those during daytime (p?<?0.001 for all). Multivariate analysis revealed a significant relationship between PWV-SDS and ferritin (R 2?=?0.269, p?=?0.006) and between carotid IMT-SDS and proteinuria (R 2?=?0.141, p?=?0.022). The LVM index was independently associated only with higher body mass index SDS (R 2?=?0.317, p?<?0.001). In addition, six patients (16 %) had multiple abnormal subclinical CVD markers, and increased subclinical CVD risk was independently associated only with higher low-density lipoprotein cholesterol (R 2?=?0.292, p?=?0.044).Conclusions
Based on these results, steroid-resistant NS children generally are at high risk of cardiovascular complications, but the increased risk is likely to be multifactorial. 相似文献104.
105.
Betul Borku Uysal MD Hande Ikitimur MD Serap Yavuzer MD Baris Ikitimur MD Harun Uysal MD Mehmet Sami Islamoglu MD Erkan Ozcan MD Emre Aktepe MD Hakan Yavuzer MD Mahir Cengiz MD 《Journal of medical virology》2020,92(11):2648-2656
To recognize the period of exaggerated cytokine response in patients with coronavirus disease 2019 (COVID-19) pneumonia, and to describe the clinical outcomes of using tocilizumab as a treatment option. The data of 12 adult COVID-19 pneumonia patients who were followed in the inpatient clinics of Biruni University Medical Faculty Hospital (Istanbul, Turkey) were retrospectively analyzed. Diagnostic tests, laboratory examinations, clinical findings, and computed tomography of the thorax imaging results were evaluated. A dramatic laboratory and clinical improvement was observed in 83% (10 out of 12) of patients after tocilizumab. In 17% (2 out of 12) of our patients, short-term ventilator support was required in the intensive care unit. The longest hospital stay was 18 days. However, in the end, all of our patients were discharged home with good health. Although arterial oxygen saturations (87.58 ± 3.12%) dropped in room air in the pre-tocilizumab period, post-tocilizumab they normalized in all patients (94.42 ± 1%). None of them had fever after tocilizumab treatment and the levels of C-reactive protein (13.08 ± 12.89) were almost within normal limits. Eosinophil values were quite low at the time of diagnosis (10 ± 17.06), but increased significantly post-tocilizumab (155.33 ± 192.69). There is currently no proven treatment for COVID-19 induced by novel coronavirus SARS-CoV-2. Based on our experience with twelve adult COVID-19 pneumonia patients, we can say that tocilizumab, an IL-6 inhibitor, is more beneficial in preventing the damage caused by excessive cytokine response in the body if administered at the right time and provides clinical and radiological recovery. 相似文献
106.
107.
108.
109.
Tülay Kamaak Beril Dilber Serap
zer Yaman Betül Diler Durgut Tuba Kurt Elif oban Elif Acar Arslan Sevim ahin Süleyman Caner Karahan Ali Cansu 《Epileptic Disord》2020,22(2):183-193
Aim: The purpose of this study was to compare HMGB‐1, TLR4, IL‐1β, IL‐1R1, and TNF‐α levels in patients with mild and severe epilepsy with those in a healthy control group. Methods: Children aged 4–17 years, diagnosed with epilepsy for at least three years and with no progressive neurological disease, metabolic disease or infection, were selected for the study. The severe epilepsy group consisted of 28 children with at least one episode a week despite receiving three or more antiepileptic drugs. The mild epilepsy group consisted of 29 children with no seizures in the previous year, receiving only one antiepileptic drug, while 27 healthy children were selected as the control group. HMGB‐1, TLR4, IL‐1R1, TNF‐α and IL‐1β levels were investigated in these three groups. The MRI findings and clinical characteristics of the patients in the epilepsy group were also compared with these markers. Results: HMGB‐1, TLR4, TNF‐α, and IL‐1β levels in the severe epilepsy group were higher than in the control group and the mild epilepsy group (p<0.05), and were higher in the mild epilepsy group than in the control group (p<0.05). IL‐1R1 was also higher in the severe epilepsy group than in the control group (p<0.05). Conclusion: In this first report to identity a possible correlation between HMGB‐1, TLR4, IL‐1β, IL‐1R1, and TNF‐α levels and severity of epilepsy, our data demonstrates that the serum level of these cytokines is higher in cases of drug‐refractory epilepsy. 相似文献
110.
Ozkan Kanat Hulya Ertas Burcu Caner 《World journal of gastrointestinal oncology》2020,12(10):1080-1090
The treatment of metastatic colorectal cancer (mCRC) harboring BRAF V600 mutations is challenging. These tumors are often refractory to standard treatment. Therefore, the patients may exhibit rapid clinical deterioration, depriving them of the chance to receive salvage therapy. In newly diagnosed patients with good performance status, the administration of an intensive chemotherapy regimen like FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) along with the antiangiogenic agent bevacizumab can modify this aggressive behavior of the disease and improve patient clinical outcomes. The recently published results of the BEACON (Binimetinib, Encorafenib, and Cetuximab Combined to Treat BRAF-Mutant Colorectal Cancer) study demonstrated that a combination therapy consisting of BRAF, epidermal growth factor receptor, and mitogen-activated protein kinase kinase inhibitors could be a useful second-or third-line alternative. This review summarizes the current treatment strategies for BRAF-mutant mCRC. 相似文献